Skip to main content
Steven Fruchtman, MD, Hematology, New York, NY

StevenMFruchtmanMD

Hematology New York, NY

Associate Professor of Hematology & Oncology, New York Medical College

Dr. Fruchtman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Fruchtman's full profile

Already have an account?

Education & Training

  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1981 - 1983
  • SUNY Health Science Center at Brooklyn
    SUNY Health Science Center at BrooklynResidency, Internal Medicine, 1977 - 1981
  • New York Medical College
    New York Medical CollegeClass of 1977

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1978 - 2026
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2003-2014
  • Top Doctors: New York Metro Area Castle Connolly, 2002-2014
  • America's Top Doctors for Cancer Castle Connolly, 2005-2007
  • Join now to see all

Publications & Presentations

PubMed

Abstracts/Posters

  • Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidin...
    Steven M. Fruchtman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)
    Steven M. Fruchtman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer
    Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial CancerMay 12th, 2023
  • Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer
    Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial CancerMay 11th, 2023
  • Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder
    Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark GelderApril 6th, 2023
  • Join now to see all

Professional Memberships